Integral Health Asset Management, LLC Macrogenics Inc Transaction History

Integral Health Asset Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$9.77 - $21.47 $488,500 - $1.07 Million	50,000 Added 11.11%	500,000 $7.36 Million
Q4 2023 Feb 14, 2024	BUY	$4.48 - $10.11 $2.02 Million - $4.55 Million	450,000 New	450,000 $4.33 Million
Q1 2022 May 12, 2022	SELL	$8.12 - $16.9 $1.06 Million - $2.2 Million	-130,000 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$15.91 - $21.88 $477,300 - $656,400	-30,000 Reduced 18.75%	130,000 $2.09 Million
Q3 2021 Nov 12, 2021	BUY	$19.74 - $28.7 $3.16 Million - $4.59 Million	160,000 New	160,000 $3.35 Million
Q2 2021 Aug 13, 2021	SELL	$20.49 - $35.63 $3.59 Million - $6.24 Million	-175,000 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$18.99 - $33.2 $1.61 Million - $2.82 Million	85,000 Added 94.44%	175,000 $5.57 Million
Q3 2020 Nov 16, 2020	BUY	$24.69 - $31.6 $493,800 - $632,000	20,000 Added 28.57%	90,000 $2.27 Million
Q2 2020 Aug 14, 2020	BUY	$5.2 - $29.12 $364,000 - $2.04 Million	70,000 New	70,000 $1.95 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Integral Health Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Integral Health Asset Management, LLC with notifications on news.